早期乳腺癌的内分泌治疗
Endocrine Therapy in Early Breast Cancer.
作者信息
Krauss Katja, Stickeler Elmar
机构信息
Breast Center, Department of Gynecology and Obstetrics, RWTH University Hospital Aachen, Aachen, Germany.
出版信息
Breast Care (Basel). 2020 Aug;15(4):337-346. doi: 10.1159/000509362. Epub 2020 Jul 21.
Abstract
BACKGROUND
Endocrine therapy with a standard duration of 5 years is well known as an effective treatment for endocrine-sensitive breast cancer.
SUMMARY
In the adjuvant setting this treatment reduces the 15-year mortality rates by about 30 and 40% with tamoxifen and aromatase inhibitor, respectively. The well-known long-term recurrence risk of luminal cancers led to multiple trials examining the benefit of extended endocrine treatment for up to 15 years. Additional benefit with extended therapy was seen for patients with high recurrence risk. Also, additional ovarian suppression for premenopausal women exhibited a significant benefit for patients at higher risk.
KEY MESSAGES
The data of the last years will be summarized and discussed, also considering the side effects of the different treatment options.
摘要
背景
标准疗程为5年的内分泌治疗是内分泌敏感型乳腺癌的有效治疗方法，这是众所周知的。
总结
在辅助治疗中，他莫昔芬和芳香化酶抑制剂分别使15年死亡率降低约30%和40%。管腔型癌症众所周知的长期复发风险促使多项试验研究长达15年的延长内分泌治疗的益处。对于复发风险高的患者，延长治疗有额外益处。此外，对绝经前女性进行额外的卵巢抑制对风险较高的患者显示出显著益处。
关键信息
将总结和讨论过去几年的数据，同时考虑不同治疗方案的副作用。
相似文献
1
Endocrine Therapy in Early Breast Cancer.
Breast Care (Basel). 2020 Aug;15(4):337-346. doi: 10.1159/000509362. Epub 2020 Jul 21.
2
Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
Breast. 2015 Nov;24 Suppl 2:S120-5. doi: 10.1016/j.breast.2015.07.027.
3
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.
J Clin Oncol. 2016 May 10;34(14):1689-701. doi: 10.1200/JCO.2015.65.9573. Epub 2016 Feb 16.
4
Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer.
Clin Breast Cancer. 2014 Jun;14(3):147-53. doi: 10.1016/j.clbc.2013.12.010. Epub 2013 Dec 27.
5
Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Breast. 2013 Aug;22 Suppl 2:S165-70. doi: 10.1016/j.breast.2013.07.032.
6
Extended endocrine therapy in premenopausal breast cancer patients: Where are we now?
Breast J. 2020 Oct;26(10):2018-2020. doi: 10.1111/tbj.13895. Epub 2020 May 29.
7
Adjuvant endocrine therapy for premenopausal women: Type and duration.
Breast. 2017 Aug;34 Suppl 1:S108-S111. doi: 10.1016/j.breast.2017.06.040. Epub 2017 Jun 29.
8
[Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].
Bull Cancer. 2000 Jun;87(6):469-90.
9
The Modern Landscape of Endocrine Therapy for Premenopausal Women with Breast Cancer.
Breast Care (Basel). 2015 Oct;10(5):312-5. doi: 10.1159/000439462. Epub 2015 Sep 11.
10
Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer.
Am Soc Clin Oncol Educ Book. 2016;35:23-32. doi: 10.1200/EDBK_159069.
引用本文的文献
1
Detection of Mutations in Tissue and Liquid Biopsy with Novel Next-Generation Sequencing and Digital Droplet PCR Assays: Insights from Multi-Center Real Life Data of Almost 6000 Patients.
Cancers (Basel). 2025 Apr 9;17(8):1266. doi: 10.3390/cancers17081266.
2
Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer.
Sci Rep. 2025 Feb 28;15(1):7220. doi: 10.1038/s41598-025-89274-9.
3
Adjuvant endocrine therapy and risk of contralateral breast cancer: a systematic review and meta-analysis of observational studies.
Cancer Causes Control. 2025 Feb;36(2):107-126. doi: 10.1007/s10552-024-01900-5. Epub 2024 Oct 9.
4
Tri-chalcone suppressed breast cancer cell proliferation and induced apoptosis through intrinsic and extrinsic pathways.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov;397(11):8993-9006. doi: 10.1007/s00210-024-03220-6. Epub 2024 Jun 14.
5
Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies.
Endocrinology. 2024 Apr 29;165(6). doi: 10.1210/endocr/bqae051.
6
Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor-Positive Postmenopausal Breast Cancer Patients in the TEAM Trial.
Clin Cancer Res. 2024 Apr 15;30(8):1509-1517. doi: 10.1158/1078-0432.CCR-23-2436.
7
Immunohistochemistry-derived subtypes of breast cancer distribution in four regions of Ethiopia.
Front Endocrinol (Lausanne). 2023 Nov 9;14:1250189. doi: 10.3389/fendo.2023.1250189. eCollection 2023.
8
Impact of Imaging Biomarkers and AI on Breast Cancer Management: A Brief Review.
Cancers (Basel). 2023 Oct 30;15(21):5216. doi: 10.3390/cancers15215216.
9
Barriers and Facilitators of Adherence to Oral Anticancer Medications Among Women with Breast Cancer: A Qualitative Study.
Patient Prefer Adherence. 2023 Nov 6;17:2821-2839. doi: 10.2147/PPA.S416843. eCollection 2023.
10
Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer.
Pharmaceuticals (Basel). 2023 Oct 16;16(10):1466. doi: 10.3390/ph16101466.
本文引用的文献
1
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
J Clin Oncol. 2020 Apr 20;38(12):1346-1366. doi: 10.1200/JCO.19.02309. Epub 2020 Jan 13.
2
Pharmacogenomics and Endocrine Therapy in Breast Cancer.
J Clin Oncol. 2020 Feb 20;38(6):525-528. doi: 10.1200/JCO.19.03119. Epub 2019 Dec 27.
3
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol. 2020 Jan;21(1):33-43. doi: 10.1016/S1470-2045(19)30786-7. Epub 2019 Dec 11.
4
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR/HER2 Breast Cancer.
Clin Cancer Res. 2020 Feb 1;26(3):566-580. doi: 10.1158/1078-0432.CCR-19-1425. Epub 2019 Oct 15.
5
Breast cancer statistics, 2019.
CA Cancer J Clin. 2019 Nov;69(6):438-451. doi: 10.3322/caac.21583. Epub 2019 Oct 2.
6
The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
Clin Transl Sci. 2020 Mar;13(2):284-292. doi: 10.1111/cts.12707. Epub 2019 Nov 9.
7
Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial.
J Clin Oncol. 2020 Feb 10;38(5):434-443. doi: 10.1200/JCO.19.00126. Epub 2019 Sep 16.
8
Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
Ann Oncol. 2019 Nov 1;30(11):1776-1783. doi: 10.1093/annonc/mdz289.
9
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
N Engl J Med. 2019 Jun 20;380(25):2395-2405. doi: 10.1056/NEJMoa1904819. Epub 2019 Jun 3.
10
Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials.
Breast. 2019 Aug;46:19-24. doi: 10.1016/j.breast.2019.04.004. Epub 2019 Apr 25.
Zotero 插件